Teladoc Health (TDOC) to Post Quarterly Earnings on Wednesday

Teladoc Health (NYSE:TDOC) is expected to post its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $615.4450 million for the quarter. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 5:00 PM ET.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The firm had revenue of $613.85 million during the quarter, compared to analyst estimates of $611.04 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The business’s quarterly revenue was down 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.53) earnings per share. On average, analysts expect Teladoc Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Teladoc Health Stock Performance

Teladoc Health stock opened at $8.89 on Tuesday. The firm’s 50 day simple moving average is $8.10 and its 200-day simple moving average is $6.52. The company has a market cap of $1.61 billion, a P/E ratio of -9.17 and a beta of 2.10. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. Teladoc Health has a fifty-two week low of $4.40 and a fifty-two week high of $9.89.

Insider Transactions at Teladoc Health

In related news, insider Carlos Nueno sold 6,196 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $47,275.48. Following the transaction, the insider owned 57,671 shares of the company’s stock, valued at approximately $440,029.73. This trade represents a 9.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Charles Divita III sold 19,132 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $145,977.16. Following the transaction, the chief executive officer owned 389,894 shares in the company, valued at approximately $2,974,891.22. This trade represents a 4.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 39,195 shares of company stock worth $299,058. Corporate insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Several hedge funds have recently bought and sold shares of TDOC. Dimensional Fund Advisors LP lifted its position in shares of Teladoc Health by 23.8% in the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock worth $53,260,000 after buying an additional 1,325,106 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of Teladoc Health during the 4th quarter worth about $9,156,000. Bridgeway Capital Management LLC acquired a new position in shares of Teladoc Health during the 2nd quarter valued at about $8,729,000. Man Group plc increased its holdings in shares of Teladoc Health by 113.8% during the 4th quarter. Man Group plc now owns 1,620,633 shares of the health services provider’s stock valued at $11,344,000 after acquiring an additional 862,454 shares during the last quarter. Finally, Nuveen LLC raised its stake in shares of Teladoc Health by 38.7% in the 4th quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock valued at $18,618,000 after acquiring an additional 742,240 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TDOC. Citigroup raised their price objective on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 5th. Bank of America boosted their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Canaccord Genuity Group raised their target price on Teladoc Health from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.57.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.